EMERCell Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

EMERCell General Information

Description

Developer of an immunotherapy product intended to implement the first steps of the pharmaceutical development. The company develops cell therapy products for oncology, advanced therapy medicinal products using a patented process to amplify and activate allogeneic natural killer cells used in association with monoclonal antibodies, thereby enabling patients to access off-the-shelf, scalable, and reproducible cell-based therapies with consistent potency and safety profiles.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 77 rue de Vaugirard
  • 75006 Paris
  • France
+33 06
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Corporate Office
  • 77 rue de Vaugirard
  • 75006 Paris
  • France
+33 06

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EMERCell Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 17-Feb-2021 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view EMERCell’s complete valuation and funding history, request access »

EMERCell Patents

EMERCell Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2998292-A1 Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease Active 11-Sep-2015
EP-3347454-A1 Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease Pending 11-Sep-2015
US-12291574-B2 Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease Active 11-Sep-2015
US-20170281681-A1 Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease Inactive 11-Sep-2015
US-20220096554-A1 Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease Active 11-Sep-2015 C07K16/2887
To view EMERCell’s complete patent history, request access »

EMERCell Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EMERCell FAQs

  • When was EMERCell founded?

    EMERCell was founded in 2013.

  • Where is EMERCell headquartered?

    EMERCell is headquartered in Paris, France.

  • What is the size of EMERCell?

    EMERCell has 3 total employees.

  • What industry is EMERCell in?

    EMERCell’s primary industry is Drug Discovery.

  • Is EMERCell a private or public company?

    EMERCell is a Private company.

  • What is EMERCell’s current revenue?

    The current revenue for EMERCell is .

  • When was EMERCell acquired?

    EMERCell was acquired on 17-Feb-2021.

  • Who acquired EMERCell?

    EMERCell was acquired by Onward Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process